Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Conditions:   Type 2 Diabetes Mellitus (T2DM);   Nonalcoholic Steatohepatitis
Interventions:   Drug: Pioglitazone;   Other: Placebo
Sponsors:   University of Florida;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 17, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine